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Purpose: The aims of the study were to characterize the signal transduction responses to platelet-activating factor (PAF)
and to monitor the downstream effects of PAF on the production of proinflammatory cytokines in human conjunctival
epithelial cells (HCECs).
Methods: The generation of inositol phosphates ([3H]IPs) from [3H]phosphoinositide (PI) hydrolysis and the mobilization
of intracellular calcium ([Ca2+]i) were evaluated using ion exchange chromatography and Fura-2 fluorescence techniques,
respectively. The production of the cytokines (interleukin-6 [IL-6], interleukin-8 [IL-8], and granulocyte macrophage
colony-stimulating factor [GM-CSF]) from PAF-stimulated HCECs was quantified using specific ELISA assays. Specific
PAF antagonists were used to study the pharmacological aspects of PAF actions in HCECs.
Results: PAF (100 nM) maximally stimulated PI turnover in HCECs by 2.3±0.02 fold (n=21) above basal levels and with
a potency (EC50) of 5.9±1.7 nM (n=4). PAF or its stabilized analog, methyl carbamyl (mc)PAF (EC50=0.8 nM), rapidly
mobilized [Ca2+]i, which peaked within 30–60 s and remained elevated for 3 min. PAF (10 nM–1 µM) stimulated the
release of the proinflammatory cytokines, IL-6, IL-8, and GM-CSF, 1.4–3.5 fold above basal levels. The effects of PAF
(100 nM) on PI turnover and [Ca2+]i were potently antagonized by the PAF antagonists, 1-o-hexadecyl-2-o-acetyl–sn-
glycero-3-phospho  (N,N,N-trimethyl)  hexanolamine  (IC50=0.69  µM;  Ki=38  nM),  methyl  2-(phenylthio)ethyl-1,4-
dihydro-2,4,6-trimethyl-pyridine-3,5-dicsrboxylate  (PCA-42481;  IC50=0.89  µM;  Ki=50  nM),  rac-3-(N-
octadecylcarbomoyl)-2-methoxy) propyl-(2-thiazolioethyl) phosphate (CV-3988; IC50=13 µM; Ki=771 nM), and (+/−)-
cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one HCl (SM-10661; IC50=14 µM; Ki=789 nM [n=3 for each antagonist]).
PAF-induced production of IL-6, IL-8, and GM-CSF from HCECs was also blocked by these PAF antagonists (IC50=4.6–
8.6 µM).
Conclusions: HCECs respond to PAF by generating IPs, mobilizing [Ca2+]i, and then secreting cytokines into the
extracellular medium. These results suggest that HCECs may be key target cells for the PAF released from conjunctival
mast cells following ocular allergic reactions. Therefore, HCECs in culture represent suitable in vitro models for the
investigation of the role of PAF in human ocular allergic and inflammatory diseases and for the discovery of therapeutically
useful PAF antagonists.
Platelet-activating factor (PAF) is an ether phospholipid,
which  is  produced  and  released  by  many  types  of  cells
including mast cells, neutrophils, eosinophils, macrophages,
and  basophils  following  noxious  stimulation  and/or  after
initiation  of  allergic  reactions  [1-4].  PAF  is  a  potent
proinflammatory  agent  causing  platelet  aggregation,
enhancing  histamine  and  serotonin  release  with  resultant
vasodilation and increased vascular permeability, increased
eosinophil and neutrophil motility, and degranulation [1-4]
leading to edema formation, hyperemia, itching, and pain [1,
5].  Based  on  these  symptomatologies,  PAF  has  been
implicated in asthma, shock and thrombosis, and in allergic
and inflammatory ocular diseases including various forms of
conjunctivitis and neovascularization [1,5]. Indeed, in terms
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of specific ocular effects, PAF has been found in the cornea,
iris, ciliary body, and retina and is released into the tear film
upon conjunctival provocation [5-7]. Topically applied PAF
causes  conjunctival  edema  and  raises  intraocular  pressure
(IOP)  [8],  and  intracamerally  injected  PAF  produces  an
inflammatory  reaction  with  pronounced  aqueous  flare,
corneal edema, and IOP changes [9]. In addition, intracorneal
injection of PAF causes a severe chemotactic response in the
cornea  and  the  surrounding  conjunctiva  [9].  PAF  that  is
exogenously added to cultured cells or rabbit corneal organ
cultures induces gene expression of cyclooxygenase-2 [10],
plasminogen activator [11,12], and matrix metalloproteinases
(MMPs) [13]. In the rat eye, PAF receptor mRNA has been
detected in the corneal epithelium [14], but little information
is available for human conjunctiva on the mRNA or protein
of the PAF receptor. While a preliminary report indicated that
specific binding sites for PAF were present on rabbit corneal
epithelial cells [15], no such information is known for human
conjunctival epithelial cells.
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1153Although  human  ocular  allergies  involve  several
different molecular and cellular mechanisms [1-4], the major
involvement  of  conjunctival  mast  cells  in  producing  and
releasing  chemical  mediators  such  as  PAF,  leukotrienes,
histamine, and other agents during allergic reactions is not
well  established  [1-3].  While  the  conjunctival
microvasculature and nociceptive nerve-endings may be the
predominant target tissues for the direct actions of PAF and
histamine, it is not clear if other cells on the ocular surface are
also influenced and/or recruited by these primary mediators
in the allergic and inflammatory cascade. Human conjunctival
epithelial cells (HCECs) may represent potential target cells
for mast cell mediators, and we have recently demonstrated
that  HCECs  respond  to  histamine  by  generating  inositol
phosphates, mobilizing intracellular calcium [16,17], and then
secreting proinflammatory cytokines like interleukin-6 (IL-6)
and interleukin-8 (IL-8) [18].
The aims of the present studies were threefold: 1) to
determine if functionally coupled PAF receptors were present
on primary cultures of HCECs isolated from multiple donors
using  [3H]phosphoinositide  (PI)  turnover  as  an  index  of
receptor activation, 2) to demonstrate possible PAF-induced
mobilization of intracellular calcium ([Ca2+]i) in HCECs, and
3) to investigate whether the activation of the latter signal
transduction mechanism in HCECs leads to the release of a
variety of proinflammatory cytokines.
METHODS
Isolation and culture of human conjunctival epithelial cells:
The  procedures  for  isolating  and  culturing  human
conjunctival epithelial cells (HCECs) from 21 post-mortem
human  donors  were  as  previously  described  with  minor
modifications [18,19]. Briefly, human conjunctival tissue was
aseptically dissected (within 8–12 h of death) and transported
from eye banks in Dexol® or Optisol® preservation medium
(Chiron Ophthalmics, Irvine, CA) in ice. Tissue from different
donors was kept separate and rinsed in phosphate buffered
saline (PBS). It was then treated with dispase (Collaborative
Research, Bedford, MA) at 10 U/ml in 50% Hanks buffered
salts and keratinocyte basal medium (KGM; Clonetics, San
Diego, CA), containing 0.05 mM calcium, at 4 °C for 24–48
h. Complete KGM was prepared by adding 30 µg/ml of bovine
pituitary  extract,  0.5  µg/ml  hydrocortisone,  0.05  µg/ml
amphotericin B and 50 µg/ml gentamicin, 5 µg/ml insulin,
10 µg/ml transferrin, and 0.05 mM calcium chloride. After
incubation  with  dispase,  the  slightly  yellow  conjunctival
epithelium  was  removed  with  a  scalpel  from  the  white
connective tissue. The epithelium was gently dissociated to
generate individual cells and washed in Dulbecco’s modified
Eagle medium (DMEM) containing 10% fetal bovine serum
using  a  centrifugation  (280x  g/10  min)/re-suspension
procedure. The cell pellet was re-suspended in a low calcium
(0.05 mM) KGM, plated into T75 flasks (collagen type IV
coated),  and  incubated  at  37  °C  under  a  humidified
atmosphere of 95% air and 5% CO2. The medium was changed
a day later and then changed every two days thereafter. The
cells became confluent in approximately 10 days at which
point they were subcultured (passage 1; P1) by rinsing with
PBS, incubating in dispase for about 20 min until the cells
detached,  washing  in  DMEM  by  centrifugation,  and  then
plating on collagen-coated 24 well culture plates (Corning/
Costar, Cambridge, MA). All subsequent experiments for PI
turnover  and  intracellular  calcium  mobilization  were
performed with the P1 cells. For the [Ca2+]i experiments, the
cells  were  cultured  on  sterilized  #0  glass  coverslips
(Biophysica  Technologies  Inc.,  Sparks,  MD)  for  three  to
seven days.
PAF-induced  PI  turnover:  Phosphoinositide  (PI)  turnover
assays  were  conducted  as  follows.  Briefly,  HCECs  were
incubated with [3H]myo-inositol (1 µCi/0.5 ml; 15–17 Ci/
mmol; Amersham, Arlington Heights, IL) in DMEM for 24 h
at 37 °C. After this time, the medium was aspirated and the
cells were rinsed with 1 ml of warm DMEM and then exposed
to PAF or methyl carbamyl (mc)PAF (10 pM–10 µM; Biomol
Inc., Plymouth Meeting, PA) in DMEM that contained 10 mM
LiCl for 60 min at 37 °C to stimulate the production and
accumulation of [3H]inositol phosphates ([3H]IPs) [16,17]. To
determine the potencies of some commercially available PAF
antagonists (Biomol Inc.), the latter drugs were added to the
cells 30 min before the addition of PAF. The medium was
aspirated at the end of the incubation, and the assay stopped
with the addition of 1 ml of ice-cold formic acid (0.1 M). After
about 15 min, 0.9 ml of the cell lysates were transferred to
Econo-columns® (Bio-Rad, Richmond, CA), which contained
1 ml AG1X8 ion-exchange resin in the formate form. The
columns were washed with deionized water (10 ml) to remove
the  free  [3H]myo-inositol,  which  was  discarded,  and  the
water-soluble  [3H]IPs  were  then  eluted  from  the  columns
using 4 ml of ammonium formate (1.2 M) made in 0.1 M
formic acid. A water-accepting scintillation fluid (15 ml) was
then added to the eluates, and the [3H]IPs were quantified by
liquid scintillation spectrometry on a beta counter at about
50% efficiency. The data obtained from these studies were
analyzed using a nonlinear, iterative, sigmoidal curve-fitting
computer program [16,17] and the appropriate means±SEM
calculated for results from several independent experiments
and from several cultures of HCECs from different donors.
The PAF antagonists used in these and other studies described
below included the following: 1-o-hexadecyl-2-o-acetyl –sn-
glycero-3-phospho  (N,N,N-trimethyl)  hexanolamine
(abbreviated  to  hexanolamine);  methyl  2-
(phenylthio)ethyl-1,4-dihydro-2,4,6-trimethyl-pyridine-3,5-
dicsrboxylate  (PCA-42481);  rac-3-(N-
octadecylcarbomoyl)-2-methoxy)  propyl-(2-thiazolioethyl)
phosphate  (CV-3988);  and  (+/−)-cis-3,5-dimethyl-2-(3-
pyridyl)thiazolidin-4-one HCl (SM-10661).
[Ca2+]i  mobilization:  Intracellular  calcium  mobilization
studies were performed as follows. Briefly, HCECs (passage
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11541) were cultured on sterilized glass coverslips (#0; Biophysica
Technologies Inc.) for three to seven days. On the day of
experiment, the cells were loaded with fura-2 acetoxymethyl
ester (Fura-2/AM; Molecular Probes Inc., Eugene, OR) by
incubating at room temperature for 30 min with Buffer A
(125 mM NaC1, 5 mM KC1, 1.8 mM CaC12, 2 mM MgC12,
0.5 mM NaH2PO4, 5 mM NaHCO3, 10 mM glucose, 0.1%
BSA, 5 mM Fura-2/AM, 10 mM HEPES, pH 7.2). After the
incubation,  the  coverslip  was  rinsed  twice  with  Buffer  B
(Buffer A without BSA or Fura-2/AM) and mounted in an
incubation  chamber  on  the  mechanical  stage  of  a  Nikon
Diaphot microscope (Nikon, Garden City, NY). The chamber
was filled with 2 ml of Buffer B at room temperature during
the experiment. At times indicated, PAF and/or antagonists
were added in volumes of 20 µl and were removed by rinsing
with 5 rinses of 2 ml each time of Buffer B. Calcium ratio
fluorometry  was  performed  using  a  DeltaScan-4000  ratio
fluorescence system (Photon Technology International, South
Brunswick, NJ) [20]. The fluorescent dye, Fura-2, within the
cells was excited by alternating between 340 nm and 380 nm
excitation wavelengths, and the intensity of the intracellular
emission  fluorescence  at  510  nm  for  each  excitation
wavelength was monitored in real time by a SIT microscope
video camera (model C2400; Hamamatsu Hamamatsu City,
Japan). The intracellular Ca2+ concentration ([Ca2+]i) of each
cell was calculated from the intensity ratio of fluorescence at
the two excitation wavelengths according to the equation of
Grynkiewicz  et  al.  [21]  and  the  appropriate  mean±SEM
calculated for results from several independent experiments
using fresh cells from new donors. In some experiments, when
the exact concentration of calcium was not critical to the
interpretation  of  the  data,  only  the  intensity  ratio  was
presented.  In  such  cases,  a  higher  ratio  indicates  higher
[Ca2+]i.
PAF-induced cytokine release: The release of cytokines and
their quantification were performed using specific ELISAs as
previously described [18]. Briefly, for each experiment, the
cells from an individual donor were trypsinized as above and
subcultured overnight at a density of 2×104 viable cells/ml per
well using fibronectin (FNC)-coated 24 well Primaria® plates
(Becton Dickerson Labware, Lincoln Park, NJ). Duplicate or
triplicate cultures were set up for each experimental group.
The following morning, the medium was replaced with a fresh
KGM medium (deficient in hydrocortisone) with or without
PAF, and the cultures were incubated at 37 °C for an additional
24 h unless otherwise specified. Supernatants were collected
at various times during the stimulation period for time-course
experiments, centrifuged at 200x g for 3 min, transferred into
separate tubes, and stored frozen at -20 °C. When the effects
of PAF antagonists were investigated, they were added to the
cells simultaneously with PAF. Cell monolayers were lysed
by freeze–thaw cycling at -70 °C followed by sonication on
ice. The lysates were clarified by centrifugation as described
and  stored  at  -20  °C.  The  cell  culture  supernatants  were
analyzed for IL-6, IL-8, and GM-CSF by ELISA (Quantikine
Kits™; R&D Systems, Minneapolis, MN) as directed by the
manufacturer. The optical density readings of the resultant
color change were measured at 450 nm (540 nm reference)
using a Bio-Tek™ microplate reader (Bio-Tek Instruments,
Winooski, VT).
Data analyses: Functional data (dpm/well; pmol/well, etc.)
were analyzed using a nonlinear, iterative, sigmoidal curve-
fitting  computer  program  (Origin®;  OriginLab  Corp.,
Northamptin, MA) [16,17]. Data from several experiments
from different donors were combined and represented as the
percentages of the maximal responses/inhibitions to provide
an overall summary of the key pharmacological data. The
molar potency (EC50) values represented the concentration of
PAF required to produce 50% of the maximal response. The
molar antagonist potency (IC50) represented the concentration
of the PAF antagonists to cause 50% inhibition of the maximal
functional  response  induced  by  PAF.  Equilibrium  drug
inhibition constants (drug dissociation constants; Kis) derived
from  the  functional  assays  represented  the  molar  drug
concentrations  required  to  produce  50%  inhibition  of  the
response while the pKi values represented the –log of this
parameter. The equilibrium antagonist potency (Ki) values
were calculated according to the equation [16,18]:
Ki= IC50/ 1 +   (Agonist concentration/Agonist EC50)
where IC50 is the concentration of the antagonist inhibiting the
PAF-induced response by 50%. All data from three or more
experiments were calculated as mean±SEM.
RESULTS
PI turnover studies: PAF (100 nM) maximally stimulated PI
turnover in primary HCECs by 2.3±0.02 fold (n=21) above
basal levels and with a potency (EC50) of 5.9±1.7 nM (n=4;
Figure 1A). For example, the [3H]IPs generated by 100 nM
PAF were 10,160±1,254 dpm (n=21) while the basal control
levels of [3H]IPs were 4,373±606 dpm (n=21). This represents
a 2.3 fold stimulation above basal levels. However, the PI
response  diminished  significantly  relative  to  the  maximal
response when the concentration of PAF was increased to 1–
10 µM (Figure 1A).
The effects of PAF (100 nM) on PI turnover were potently
and  concentration-dependently  blocked  by  the  PAF
antagonists, hexanolamine (IC50=694 nM; Ki=38 nM; -log Ki
[pKi]=7.4±0.12),  PCA-42481  (IC50=897  nM;  Ki=50  nM;
pKi=7.4±0.23),  CV-3988  (IC50=13.2  µM;  Ki=771  nM;
pKi=6.1±0.21), and SM-10661 (IC50=14 µM; Ki=789 nM;
pKi=6.1±0.01  [n=3  independent  experiments  for  each
antagonist]; Figure 1B).
[Ca2+]i mobilization studies: PAF was observed to stimulate
[Ca2+]i  mobilization  in  most  cells  studied.  However,  the
cellular responses varied for 10 nM PAF, ranging from no
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1155response (Figure 2A), a rapid response within a few seconds
followed by response decay (Figure 2B), a rapid response
followed by sustained [Ca2+]i mobilization (Figure 2C), and a
rapid response followed by oscillatory behavior (Figure 2D).
The predominant type of response, however, was that shown
in Figure 2C. The [Ca2+]i mobilized in 76 cells peaked after
treatment with 10 nM of PAF or mcPAF, which was then
followed by a sustained elevated plateau level lasting at least
15 min (Figure 2C; Figure 3A). During the current studies, the
mean resting [Ca2+]i in primary HCECs was found to be 57±8
nM (mean±SEM, n=23), and this increased to different levels
depending on the cell studied and the concentration of PAF
added to the incubation medium.
PAF or mcPAF caused an increase in [Ca2+]i in most
primary HCECs in a concentration-dependent manner (Figure
3B). A detectable increase in [Ca2+]i was observed when 0.1
nM of PAF was added to the HCECs, maximal responses to
PAF in PI (Figure 1A) and Ca2+ (Figure 3B) assays were
induced  by  100  nM  PAF  from  a  concentration-response
viewpoint. Cumulative concentration-response curves were
constructed  for  [Ca2+]i  mobilization  by  plotting  the  peak
responses versus the corresponding PAF concentrations (e.g.,
Figure 3C). The mean EC50 value for PAF was calculated to
be 0.81 nM (-log EC50 [pEC50]=9.09±0.18, n=14). The mean
peak [Ca2+]i mobilized by 10 nM PAF was 622±82 nM (n=23),
and the mean peak [Ca2+]i mobilized by 10 nM mcPAF was
792±140 nM (n=4). These potency values correlated well with
the actions of PAF on PI turnover described above. Since the
effects of PAF and mcPAF on [Ca2+]i mobilization in these
cells  were  essentially  identical,  data  obtained  for  the  two
compounds  were  pooled  and  analyzed  together  in  the
following studies.
Significant desensitization of the PAF-induced [Ca2+]i
mobilization responses was observed when the cells were
treated repeatedly with PAF or mcPAF. Typically, the second
Figure 1. Effect of PAF on PI turnover and blockade of this response
by PAF antagonists in HCECs. The concentration-dependency of
PAF-induced PI turnover is shown in A while the antagonism of PAF
(10 nM)-stimulated PI turnover by different concentrations of four
PAF antagonists is shown in B. Data are presented as mean±SEM
from three or more experiments. Hexa=hexanolamine.
treatment with PAF generated only 0%−20% of the response
of the first treatment (data not shown). Extensive rinsing of
the cells or a long waiting period (up to 30 min) between the
agonist  additions  did  not  eliminate  the  desensitization
phenomenon. Thus, the same cells were not used for multiple
agonist stimulations.
To confirm that the [Ca2+]i mobilizing effect of PAF was
mediated by specific PAF receptors on HCECs, PCA-42481
(a PAF antagonist) was used to antagonize the PAF-induced
response. Based on its blockade of PAF-activated PI turnover
(Figure 1B), 10 µM PCA-42481 was expected to completely
block the action of PAF or mcPAF in the HCECs. Indeed,
pretreatment of 25 HCECs with 10 µM PCA-42481 followed
by  the  addition  of  PAF  (10  nM)  resulted  in  minimal
mobilization  of  [Ca2+]i  (Figure  4A),  indicating  effective
blockade of the PAF receptor and its subsequent coupling to
phospholipase C. PCA-42481 effectively and immediately
antagonized  the  PAF-induced  [Ca2+]i  mobilization  when
added after the initiation of the PAF-induced response in 14
cells (e.g., Figure 4B,C).
Figure 2. Representative different calcium responses of HCECs to
PAF. PAF (10 nM) was added at 0 min. The y-axis shows the
intensity ratio of fluorescence at the two excitation wavelengths of a
single cell. High ratio indicates higher [Ca2+]i. A depicts a minimal
response of a cell to PAF. B shows a rapid response to PAF followed
by a relatively rapid decay of the [Ca2+]i mobilization response. C
displays a PAF-induced [Ca2+]i mobilization response that lasts for
at least 16 min. D shows an apparent oscillatory [Ca2+]i mobilization
pattern in an HCEC. The basal control effects with just the vehicle
resembled the lack of response in A.
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1156Since  initial  studies  indicated  that  some  HCECs
responded  to  PAF  by  exhibiting  an  apparent  oscillatory
[Ca2+]i mobilization pattern (Figure 2D), a more extensive
evaluation of this phenomenon was investigated. Figure 5A
depicts the temporal changes in [Ca2+]i levels, which were
visualized in pseudocolor, in three HCECs that were in close
proximity  of  each  other  when  exposed  to  10  nM  PAF.
Followed over time, while cells #1 and #2 showed robust
cyclic oscillatory increases and decreases in [Ca2+]i (Figure
5B), cell #3 exhibited a relatively small increase in [Ca2+]i at
the onset but this declined over time and remained slightly
elevated above basal levels (Figure 5B).
Figure  3.  Effects  of  PAF  on  [Ca2+]i  in  HCECs.  A  shows
representative changes in [Ca2+]i of a single cell. B shows the effects
of adding various concentrations of PAF to HCECs at different time
points and the changes in [Ca2+]i. Wash=drug removal by rinsing the
cells with 5 rinses of 2 ml each time with assay buffer. C shows the
concentration-response curve for PAF obtained by plotting peak
calcium responses after PAF treatment versus the corresponding
PAF  concentrations.  Resting  intracellular  calcium  concentration
defines 0% response and calcium concentration after 100 nM PAF
defines 100% maximum response. In C, each symbol (filled circle)
represents the mean±SEM (n=6).
PAF-induced cytokine release: In a time-dependent manner,
PAF  significantly  increased  the  release  of  IL-6  and  IL-8.
(Figure 6). For IL-6 and IL-8, the first phase of release was
linear up to 8 h and the second phase was linear up to 24 h
following  the  addition  of  PAF  (Figure  6).  Quantitative
determination of cytokines released after 24 h following the
addition of PAF yielded the following combined data from
several  experiments  (pg/ml):  basal IL-6=151±33, +PAF (1
µM) = 415±78;  basal IL-8 = 479±77,  +PAF (1 µM) = 1403
±220;   basal   GM-CSF = 44±19,  +PAF   (1 µM) = 156±42 
(1.4–3.5   fold   above   basal;   all   mean±SEM from four
to   six   experiments   using   HCECs  from   four   to   six
different donors; Figure 7). The estimated potency of PAF in
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Figure  4.  Effect  of  a  PAF  antagonist,  PCA,  on  PAF-stimulated
[Ca2+]i mobilization in HCECs. Tracings of representative singe cells
are shown. The y-axis shows the intensity ratio of fluorescence at the
two excitation wavelengths of a single cell. Higher ratio indicates
higher  [Ca2+]i.  Additions  of  various  compounds  at  various  time
points are indicated. A shows how pretreatment of HCECs with PCA
(10  µM)  blocked  the  PAF-induced  effect.  Similar  results  were
obtained in a total of 25 cells. B shows how the PAF-induced elevated
[Ca2+]i  was  eliminated  immediately  upon  the  addition  of  PCA.
Similar results were obtained in a total of 14 cells. C shows how the
PAF-induced  oscillation  of  [Ca2+]i  mobilization  was  eliminated
when PCA was added. Similar results were obtained in a total of
seven cells.stimulating the secretion of these cytokines using cells from
different donors over the 24 h stimulation period was 108±48
nM (n=6; Figure 7).
It was noticeable that treatment of HCECs with 10 µM
PAF for 24 h resulted in significantly reduced cytokine release
relative to that induced by 10 nM–1 µM PAF (Figure 7).
Trypan blue exclusion experiments revealed that the 24 h
exposure of HCECs to 10 µM PAF caused a total loss of cell
viability, and thus, this concentration of PAF was toxic over
this period of stimulation. However, the mechanism of cell
death induced by 10 µM PAF was not studied here. This
profile of results matched those pertaining to the effects of
PAF at different concentrations on PI hydrolysis in HCECs.
High  concentrations  of  PAF  produce  a  lower  response,
presumably due to the toxic effects of PAF (Figure 1).
The PAF-induced (1 µM) secretion of IL-6, IL-8, and
GM-CSF from the HCECs was antagonized by CV-3988 and
PCA-42481 in a concentration-dependent (1–10 µM) manner
in two separate experiments using HCECs from two different
donors (Figure 8). The potencies (IC50s) of CV-3988 and
PCA-42481 for blocking the PAF-induced cytokine release
from HCECs were 4.6–8.6 µM (p<0.05–0.001).
DISCUSSION
The data presented herein have clearly shown the presence of
functionally  coupled  PAF  receptors  in  primary  HCEC
cultures isolated from several post-mortem human donor eyes.
The utilization of PI turnover, calcium ratio fluorometry, and
cytokine ELISA techniques have helped delineate the signal
Figure 5. Differential temporal changes in [Ca2+]i in HCECs exposed
to PAF. A: The pseudocolor ratio images of fura-2 loaded HCECs
show time-dependent changes of [Ca2+]i after 10 nM PAF treatment.
PAF was added at time 0. The spectrum on the right indicates a
calculated calcium concentration represented by each color. Note
that [Ca2+]i of cells #1 and #2 oscillated after an initial peak whereas
cell #3 mainly had a sustained elevation of calcium concentration
during the 15 min recording. B: Temporal changes in [Ca2+]i in the
HCECs exposed to 10 nM PAF are shown. PAF was administered at
time  0.  The  oscillatory  nature  of  [Ca2+]i  mobilization  is  readily
apparent in cell #1 and #2.
transduction mechanisms and downstream biological events
associated  with  these  receptors  in  these  particular  cells.
Therefore,  the  PAF  receptors  on  HCECs  are  positively
coupled to phospholipase C, which hydrolyzes membrane
phosphoinositides  to  generate  inositol  phosphates.  Of  the
latter, the inositol trisphosphate [22] most likely initiated the
release of calcium from intracellular stores, which may further
increase the influx of extracellular calcium, and cause the
subsequent secretion of the cytokines from the HCECs. The
fact that the nanomolar potencies of PAF and mcPAF activate
all  three  cellular  functions  strongly  suggests  that  the
biochemical cascade of events mentioned above is closely
connected with the pathological roles of the PAF receptors in
these cells. These potencies correlate well with the amounts
of  PAF  measured  in  the  tears  of  ocular  allergic  patients
following conjunctival provocation or in post-alkali burned
rabbit eyes [5,10] or in the eyes of sensitized guinea pigs after
topical ocular treatment with ovalbumin [7]. Additionally, we
demonstrated that all three signal transduction/biological end
responses  induced  by  PAF  were  blocked  concentration-
dependently by more than three structurally different PAF
antagonists  (hexanolamine,  PCA-42481,  CV-3988,  and
SM-10661). While the predominant effect of PAF in the rabbit
cornea  appears  to  be  to  activate  the  phospholipase  A2/
cyclooxygenase pathway [5] and to release leukotrienes that
cause conjunctivitis [23], the work presented here has shown
Figure 6. Time-course of cytokine release in HCECs exposed to PAF.
The levels of various cytokines (IL-6, IL-8, and GM-CSF) were
determined by specific ELISA assays when PAF (1 µM) was added
to HCECs isolated from different donor eyes. Data are shown as
mean±SEM from three or more experiments. For reference purposes,
the basal levels of each cytokine measured were as follows (pg/ml):
IL-6=151±33; IL-8=479±77; GM-CSF=44±19.
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HCECs to release cytokines. However, the activation of the
phospholipase A2/cyclooxygenase pathway by PAF in the
HCECs cannot be ruled out at this stage and requires further
study.
PAF receptor agonists stimulated [Ca2+]i mobilization in
these  cells  in  a  concentration-dependent  and  antagonist-
reversible  manner.  We  have  demonstrated  previously  that
histamine also increases [Ca2+]i mobilization in these cells
[16,17].  However,  the  time-courses  of  calcium  responses
inducted by PAF and histamine were very different. Elevation
of [Ca2+]i peaked within 5−10 s after histamine treatment
while PAF treatment required between 1−2 min for calcium
levels to reach its maximum in the responsive cells. This
difference may be explained by the fact that PAF analogs have
a higher degree of freedom in their molecular structures than
histamine. It may take longer for a PAF molecule to reach its
optimal  conformation  for  interacting  with  its  receptor,  to
recruit phospholipase C, and to liberate intracellular inositol
phosphates  from  the  membrane  phospholipids.  The  latter
hypothesis is also perhaps supported by the fact that HCECs
responded uniformly to histamine where it caused a single
[Ca2+]i peak followed by a sustained elevation of [Ca2+]i in
almost all cells tested [17] whereas there were at least four
different types of cell responses to PAF in the current study.
The  multiple  responses  to  PAF  in  the  HCECs  are
fascinating. As stated above, the cells were morphologically
similar  under  microscopic  observation.  Our  previous
Figure 7. PAF-induced production of various cytokines in HCECs.
Concentration-response studies were conducted with PAF in HCECs
isolated from different donor eyes, and the concentrations of IL-6
(A), IL-8 (B), and GM-CSF (C) released into the culture medium
were  determined  by  specific  ELISA  assays.  The  levels  of  the
cytokines produced by buffer alone or by PAF itself are also shown.
Data are shown as mean±SEM from three or more experiments.
a=p<0.05; b=p<0.01; c=p<0.001, each p value relative to the control.
publication  also  shows  that  they  were  essentially
phenotypically  homogenous  as  indicated  by  the  similar
distribution of various selective antigens in all cells, as shown
by immunohistochemistry [19]. It is not known at this time if
the cells were at different stages of the cell cycle and if that
contributes  to  their  different  [Ca2+]i  responses.  It  is  also
possible  that  the  cell  responses  were  affected  by  their
microenvironment. For example, a particular class of response
may require the presence of a co-factor that is released by
neighboring cells. If so, the location of a cell in the culture
plate in relation to other cells will determine its response to
PAF.  Future  studies  are  being  planned  to  address  these
hypotheses.
Among the four different calcium responses to PAF, the
most  interesting  one  was  the  PAF-induced  oscillations  of
[Ca2+]i. According to Berridge [22,24], the oscillatory patterns
in these cells can be classified as transient oscillations but not
sinusoidal oscillations. The properties of these patterns agree
with  a  two  pool  calcium  store  model  [22,24],  whose
mathematical representation was presented by Dupont et al.
[25].  In  this  model,  an  agonist-induced  increase  in  IP3
stimulates  the  release  of  calcium  from  an  IP3-sensitive
intracellular calcium storage site into the cytoplasm. Initially,
this released calcium is quickly taken up by an IP3-insensitive
calcium  store.  However,  after  such  a  store  is  full,  the
subsequent accumulation of calcium in the cytoplasm can then
activate a rapid calcium-induced calcium release from the
Figure 8. Antagonism of PAF-induced cytokine release in HCECs.
Concentration-response  studies  were  conducted  with  two  PAF
antagonists (CV-3988 and PC-42481) against a fixed concentration
of PAF (1 µM) in HCECs isolated from different donor eyes, and the
concentrations of IL-6, IL-8, and GM-CSF released into the culture
medium were determined by specific ELISA assays. The levels of
the cytokines produced by buffer alone or by PAF itself are also
shown.  Data  are  shown  as  mean±SEM  from  three  or  more
experiments. a=p<0.05; b=p<0.01, and c=p<0.001, each p value
relative to the control. The PAF antagonists by themselves did not
influence cytokine release.
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calcium  spike.  The  recovery  of  the  cytoplasmic  calcium
occurs  with  extrusion  across  the  plasma  membrane.  The
continuous presence of the agonist and IP3 initiates another
cycle  of  calcium  release  and  thus  repetitive  spikes  and
oscillations of cytoplasmic calcium concentration continue. It
is presently not clear if these steps were present in the HCECs
after PAF treatment. Future studies will endeavor to address
this issue.
Exogenously added PAF to HCECs resulted in a time-
and  concentration-dependent  secretion  of  the
proinflammatory cytokines, IL-6, IL-8, and GM-CSF. Unlike
the signal cascade events discussed above, several hours were
required  for  the  cytokines  to  be  released.  This  is  not
unprecedented since it is likely that the upregulation of gene
expression and protein synthesis of the cytokines had to occur
over a period of time as demonstrated in other cell types and
in  response  to  various  secretagogues  including  histamine,
calcium ionophore, phorbol ester, and bradykinin [18,26,27].
PAF-induced  cytokine  synthesis  and  secretion  has  the
potential to amplify acute inflammatory responses and to lead
to the chemosis of neutrophils, basophils, and T-lymphocytes
and the potentiation of expression of adhesion molecules,
proinflammatory  enzymes,  and  to  cause  the  release  of
additional cytokines [28-30]. Furthermore, PAF can induce
eosinophil accumulation and enhance the expression of PAF
receptors, which leads to increased vascular permeability,
edema, and itching [31-33].
In summary, PAF potently activates the phospholipase C-
coupled signal cascade system to initiate the synthesis and
secretion of numerous proinflammatory cytokines in HCECs.
Therefore, in addition to the direct deleterious effects of PAF
on the ocular surface epithelial cells such as apoptosis [34],
corneal  remodeling  [35],  and  neovascularization  [36],  the
further amplification of its downstream effects due to the
release  of  cytokines  make  PAF  a  powerful  inflammatory
agent that is implicated in allergic conjunctivitis, pain, and
neovascularization of the ocular surface [37-39]. Clearly, PAF
receptor antagonists represent useful therapeutic agents to
combat ocular surface disorders where PAF may be released
into the tear film.
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